Source comparison
Hexarelin vs Other Growth Hormone Secretagogues — Potency and Selectivity
The growth hormone secretagogue class includes multiple peptides with varying receptor selectivity, GH release amplitude, and side effect profiles. Hexarelin for fat loss sits at the high end of potency but also carries the highest risk of cortisol and prolact
This comparison does not assign a generated winner or score.
- The growth hormone secretagogue class includes multiple peptides with varying receptor selectivity, GH release amplitude, and side effect profiles. Hexarelin for fat loss sits at the high end of potency but also carries the highest risk of cortisol and prolactin co-secretion, particularly at doses exceeding 100 mcg per administration. Ipamorelin, by contrast, is considered the most selective GH secretagogue. It produces robust GH release with minimal cortisol or prolactin elevation, making it preferable for long-term protocols where hypothalamic-pituitary-adrenal (HPA) axis suppression is a concern. GHRP-2 and GHRP-6 fall between hexarelin and ipamorelin in terms of GH amplitude and side effect burden.
- Peak GH release following hexarelin administration (2 mcg/kg) typically reaches 15–25 ng/mL in responsive individuals, compared to 8–15 ng/mL with ipamorelin at equivalent dosing. However, hexarelin's prolactin response can elevate plasma prolactin by 30–50% above baseline, which may interfere with dopamine signaling and, in chronic use, contribute to libido suppression or gynecomastia in susceptible males. Ipamorelin produces less than 10% prolactin elevation at therapeutic doses, making it the safer choice for extended fat loss protocols lasting 12+ weeks. For short-term applications (4–6 weeks) where maximal GH output is prioritized, hexarelin's superior potency may justify the trade-off.
- Another consideration: receptor desensitization. Chronic daily administration of hexarelin leads to progressive attenuation of GH response over 8–12 weeks, a phenomenon documented in multiple studies. This desensitization appears to result from GHSR-1a receptor downregulation in response to sustained agonist exposure. Cycling protocols. 5 days on, 2 days off, or 4 weeks on, 2 weeks off. Are commonly employed to preserve receptor sensitivity. Ipamorelin exhibits slower desensitization kinetics, likely due to its more selective receptor profile and lower constitutive activity at GHSR-1a.
- For researchers and clinicians exploring hexarelin for fat loss, the comparison table below summarizes key pharmacological differences between commonly used GH secretagogues. Real Peptides offers research-grade formulations of all compounds listed, synthesized under USP standards with third-party purity verification available on request.